Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 57Carcinoma, Hepatocellular 45Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Lung Neoplasms 10Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Esophageal Neoplasms 9Advanced Gastric Cancer 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Liver Neoplasms 5Glioma 5Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

lenvatinib 1camrelizumab 1apatinib 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1ALT-803 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Triple Negative Breast Cancer × apatinib × Clear all
NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Fujian Cancer Hospital

Phase 1/2 Recruiting
29 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡